Franziska Michor, PhD

A paracrine circuit of IL-1ß/IL-1R1 between myeloid and tumor cells drives genotype-dependent glioblastoma progression. J Clin Invest. 2023 Sep 21. View in: Pubmed

H3K36 methylation maintains cell identity by regulating opposing lineage programmes. Nat Cell Biol. 2023 Aug; 25(8):1121-1134. View in: Pubmed

Tutorial: integrative computational analysis of bulk RNA-sequencing data to characterize tumor immunity using RIMA. Nat Protoc. 2023 08; 18(8):2404-2414. View in: Pubmed

Phase I study of a novel glioblastoma radiation therapy schedule exploiting cell-state plasticity. Neuro Oncol. 2023 06 02; 25(6):1100-1112. View in: Pubmed

Brief Report: Combination of Osimertinib and Dacomitinib to Mitigate Primary and Acquired Resistance in EGFR-Mutant Lung Adenocarcinomas. Clin Cancer Res. 2023 04 14; 29(8):1423-1428. View in: Pubmed

Mechanisms of response and resistance to combined decitabine and ipilimumab for advanced myeloid disease. Blood. 2023 04 13; 141(15):1817-1830. View in: Pubmed

Single-cell heterogeneity of EGFR and CDK4 co-amplification is linked to immune infiltration in glioblastoma. Cell Rep. 2023 03 28; 42(3):112235. View in: Pubmed

T-REX17 is a transiently expressed non-coding RNA essential for human endoderm formation. Elife. 2023 01 31; 12. View in: Pubmed

JAK-STAT Signaling in Inflammatory Breast Cancer Enables Chemotherapy-Resistant Cell States. Cancer Res. 2023 01 18; 83(2):264-284. View in: Pubmed

Breast cancer prevention by short-term inhibition of TGFß signaling. Nat Commun. 2022 12 07; 13(1):7558. View in: Pubmed

Genomic analysis of early-stage lung cancer reveals a role for TP53 mutations in distant metastasis. Sci Rep. 2022 Nov 09; 12(1):19055. View in: Pubmed

Author Correction: Identification of optimal dosing schedules of dacomitinib and osimertinib for a phase I/II trial in advanced EGFR-mutant non-small cell lung cancer. Nat Commun. 2022 Sep 23; 13(1):5579. View in: Pubmed

In vivo genome-wide CRISPR screening in murine acute myeloid leukemia uncovers microenvironmental dependencies. Blood Adv. 2022 09 13; 6(17):5072-5084. View in: Pubmed

Spatial intra-tumor heterogeneity is associated with survival of lung adenocarcinoma patients. Cell Genom. 2022 Aug 10; 2(8). View in: Pubmed

Designing optimal allocations for cancer screening using queuing network models. PLoS Comput Biol. 2022 05; 18(5):e1010179. View in: Pubmed

Barcoded bulk QTL mapping reveals highly polygenic and epistatic architecture of complex traits in yeast. Elife. 2022 02 11; 11. View in: Pubmed

Transcriptional differences between JAK2-V617F and wild-type bone marrow cells in patients with myeloproliferative neoplasms. Exp Hematol. 2022 03; 107:14-19. View in: Pubmed

Response to comment on "Genomic epidemiology of superspreading events in Austria reveals mutational dynamics and transmission properties of SARS-CoV-2". Sci Transl Med. 2021 Oct 27; 13(617):eabj3222. View in: Pubmed

Systematic tissue collection during clinical breast biopsy is feasible, safe and enables high-content translational analyses. NPJ Precis Oncol. 2021 Sep 21; 5(1):85. View in: Pubmed

Dissecting dual roles of MyoD during lineage conversion to mature myocytes and myogenic stem cells. Genes Dev. 2021 09 01; 35(17-18):1209-1228. View in: Pubmed

Topological isolation of developmental regulators in mammalian genomes. Nat Commun. 2021 08 12; 12(1):4897. View in: Pubmed

Identification of optimal dosing schedules of dacomitinib and osimertinib for a phase I/II trial in advanced EGFR-mutant non-small cell lung cancer. Nat Commun. 2021 06 17; 12(1):3697. View in: Pubmed

The impact of tumor epithelial and microenvironmental heterogeneity on treatment responses in HER2+ breast cancer. JCI Insight. 2021 06 08; 6(11). View in: Pubmed

Combined epigenetic and metabolic treatments overcome differentiation blockade in acute myeloid leukemia. iScience. 2021 Jun 25; 24(6):102651. View in: Pubmed

Impact of HER2 Heterogeneity on Treatment Response of Early-Stage HER2-Positive Breast Cancer: Phase II Neoadjuvant Clinical Trial of T-DM1 Combined with Pertuzumab. Cancer Discov. 2021 10; 11(10):2474-2487. View in: Pubmed

Progression signature underlies clonal evolution and dissemination of multiple myeloma. Blood. 2021 04 29; 137(17):2360-2372. View in: Pubmed

Computational modelling of perivascular-niche dynamics for the optimization of treatment schedules for glioblastoma. Nat Biomed Eng. 2021 04; 5(4):346-359. View in: Pubmed

Breast tumours maintain a reservoir of subclonal diversity during expansion. Nature. 2021 04; 592(7853):302-308. View in: Pubmed

A Quantitative Paradigm for Decision-Making in Precision Oncology. Trends Cancer. 2021 04; 7(4):293-300. View in: Pubmed

Reconstructing the Lineage Histories and Differentiation Trajectories of Individual Cancer Cells in Myeloproliferative Neoplasms. Cell Stem Cell. 2021 03 04; 28(3):514-523.e9. View in: Pubmed

How Does Large-Scale Genomic Analysis Shape Our Understanding of COVID Variants in Real Time? Cell Syst. 2021 02 17; 12(2):109-111. View in: Pubmed

Imaging dynamic mTORC1 pathway activity in vivo reveals marked shifts that support time-specific inhibitor therapy in AML. Nat Commun. 2021 01 11; 12(1):245. View in: Pubmed

Genomic epidemiology of superspreading events in Austria reveals mutational dynamics and transmission properties of SARS-CoV-2. Sci Transl Med. 2020 12 09; 12(573). View in: Pubmed

Circadian clock effects on cellular proliferation: Insights from theory and experiments. Curr Opin Cell Biol. 2020 12; 67:17-26. View in: Pubmed

ESTIpop: a computational tool to simulate and estimate parameters for continuous-time Markov branching processes. Bioinformatics. 2020 08 01; 36(15):4372-4373. View in: Pubmed

Pharmacokinetic Profiles Determine Optimal Combination Treatment Schedules in Computational Models of Drug Resistance. Cancer Res. 2020 08 15; 80(16):3372-3382. View in: Pubmed

Accelerating massively parallel hemodynamic models of coarctation of the aorta using neural networks. Sci Rep. 2020 06 11; 10(1):9508. View in: Pubmed

Synthetic Lethal and Resistance Interactions with BET Bromodomain Inhibitors in Triple-Negative Breast Cancer. Mol Cell. 2020 06 18; 78(6):1096-1113.e8. View in: Pubmed

Acquired resistance to combined BET and CDK4/6 inhibition in triple-negative breast cancer. Nat Commun. 2020 05 11; 11(1):2350. View in: Pubmed

Drug Sensitivity and Allele Specificity of First-Line Osimertinib Resistance EGFR Mutations. Cancer Res. 2020 05 15; 80(10):2017-2030. View in: Pubmed

Ascl2-Dependent Cell Dedifferentiation Drives Regeneration of Ablated Intestinal Stem Cells. Cell Stem Cell. 2020 03 05; 26(3):377-390.e6. View in: Pubmed

DIFFpop: a stochastic computational approach to simulate differentiation hierarchies with single cell barcoding. Bioinformatics. 2019 10 01; 35(19):3849-3851. View in: Pubmed

Mathematical modeling reveals alternative JAK inhibitor treatment in myeloproliferative neoplasms. Haematologica. 2020 03; 105(3):e91-e94. View in: Pubmed

Subclonal cooperation drives metastasis by modulating local and systemic immune microenvironments. Nat Cell Biol. 2019 07; 21(7):879-888. View in: Pubmed

Computational modeling of pancreatic cancer patients receiving FOLFIRINOX and gemcitabine-based therapies identifies optimum intervention strategies. PLoS One. 2019; 14(4):e0215409. View in: Pubmed

Stochastic Evolution of Pancreatic Cancer Metastases During Logistic Clonal Expansion. JCO Clin Cancer Inform. 2019 03; 3:1-11. View in: Pubmed

KDM5 Histone Demethylase Activity Links Cellular Transcriptomic Heterogeneity to Therapeutic Resistance. Cancer Cell. 2019 Feb 11; 35(2):330-332. View in: Pubmed

Hidden heterogeneity and circadian-controlled cell fate inferred from single cell lineages. Nat Commun. 2018 12 18; 9(1):5372. View in: Pubmed

Computational Model of Progression to Multiple Myeloma Identifies Optimum Screening Strategies. JCO Clin Cancer Inform. 2018 12; 2:1-12. View in: Pubmed

Currently available bulk sequencing data do not necessarily support a model of neutral tumor evolution. Nat Genet. 2018 12; 50(12):1620-1623. View in: Pubmed

KDM5 Histone Demethylase Activity Links Cellular Transcriptomic Heterogeneity to Therapeutic Resistance. Cancer Cell. 2018 12 10; 34(6):939-953.e9. View in: Pubmed

Fitness variation in isogenic populations leads to a novel evolutionary mechanism for crossing fitness valleys. Commun Biol. 2018; 1:151. View in: Pubmed

Unravelling subclonal heterogeneity and aggressive disease states in TNBC through single-cell RNA-seq. Nat Commun. 2018 09 04; 9(1):3588. View in: Pubmed

A PDGFRa-driven mouse model of glioblastoma reveals a stathmin1-mediated mechanism of sensitivity to vinblastine. Nat Commun. 2018 08 06; 9(1):3116. View in: Pubmed

Phase II study of ruxolitinib, a selective JAK1/2 inhibitor, in patients with metastatic triple-negative breast cancer. NPJ Breast Cancer. 2018; 4:10. View in: Pubmed

Increased HOXA5 expression provides a selective advantage for gain of whole chromosome 7 in IDH wild-type glioblastoma. Genes Dev. 2018 04 01; 32(7-8):512-523. View in: Pubmed

Mathematical modeling identifies optimum lapatinib dosing schedules for the treatment of glioblastoma patients. PLoS Comput Biol. 2018 01; 14(1):e1005924. View in: Pubmed

The Warburg effect: persistence of stem-cell metabolism in cancers as a failure of differentiation. Ann Oncol. 2018 01 01; 29(1):264-270. View in: Pubmed

Nuclear topology modulates the mutational landscapes of cancer genomes. Nat Struct Mol Biol. 2017 Nov; 24(11):1000-1006. View in: Pubmed

mTOR and HDAC Inhibitors Converge on the TXNIP/Thioredoxin Pathway to Cause Catastrophic Oxidative Stress and Regression of RAS-Driven Tumors. Cancer Discov. 2017 12; 7(12):1450-1463. View in: Pubmed

Epigenetic restriction of extraembryonic lineages mirrors the somatic transition to cancer. Nature. 2017 09 28; 549(7673):543-547. View in: Pubmed

Analysis of somatic microsatellite indels identifies driver events in human tumors. Nat Biotechnol. 2017 Oct; 35(10):951-959. View in: Pubmed

Estimating mono- and bi-phasic regression parameters using a mixture piecewise linear Bayesian hierarchical model. PLoS One. 2017; 12(7):e0180756. View in: Pubmed

SIApopr: a computational method to simulate evolutionary branching trees for analysis of tumor clonal evolution. Bioinformatics. 2017 Jul 15; 33(14):2221-2223. View in: Pubmed

Immune Escape in Breast Cancer During In Situ to Invasive Carcinoma Transition. Cancer Discov. 2017 10; 7(10):1098-1115. View in: Pubmed

Bisulfite-independent analysis of CpG island methylation enables genome-scale stratification of single cells. Nucleic Acids Res. 2017 Jun 02; 45(10):e77. View in: Pubmed

Pharmacokinetics and Drug Interactions Determine Optimum Combination Strategies in Computational Models of Cancer Evolution. Cancer Res. 2017 07 15; 77(14):3908-3921. View in: Pubmed

The Mutational Landscape of Circulating Tumor Cells in Multiple Myeloma. Cell Rep. 2017 04 04; 19(1):218-224. View in: Pubmed

Mathematical Modeling Links Pregnancy-Associated Changes and Breast Cancer Risk. Cancer Res. 2017 06 01; 77(11):2800-2809. View in: Pubmed

Distance in cancer gene expression from stem cells predicts patient survival. PLoS One. 2017; 12(3):e0173589. View in: Pubmed

Phase 1 study of twice weekly pulse dose and daily low-dose erlotinib as initial treatment for patients with EGFR-mutant lung cancers. Ann Oncol. 2017 02 01; 28(2):278-284. View in: Pubmed

Proceedings of the third international molecular pathological epidemiology (MPE) meeting. Cancer Causes Control. 2017 02; 28(2):167-176. View in: Pubmed

Clonal Hematopoiesis Associated With Adverse Outcomes After Autologous Stem-Cell Transplantation for Lymphoma. J Clin Oncol. 2017 May 10; 35(14):1598-1605. View in: Pubmed

Probabilistic Modeling of Reprogramming to Induced Pluripotent Stem Cells. Cell Rep. 2016 12 20; 17(12):3395-3406. View in: Pubmed

A computational strategy to adjust for copy number in tumor Hi-C data. Bioinformatics. 2016 12 15; 32(24):3695-3701. View in: Pubmed

Punctuated copy number evolution and clonal stasis in triple-negative breast cancer. Nat Genet. 2016 10; 48(10):1119-30. View in: Pubmed

ABCG2 regulates self-renewal and stem cell marker expression but not tumorigenicity or radiation resistance of glioma cells. Sci Rep. 2016 07 26; 6:25956. View in: Pubmed

Mathematical modeling of erythrocyte chimerism informs genetic intervention strategies for sickle cell disease. Am J Hematol. 2016 09; 91(9):931-7. View in: Pubmed

Myeloma Cell Dynamics in Response to Treatment Supports a Model of Hierarchical Differentiation and Clonal Evolution. Clin Cancer Res. 2016 Aug 15; 22(16):4206-4214. View in: Pubmed

The mathematics of cancer: integrating quantitative models. Nat Rev Cancer. 2015 Dec; 15(12):730-45. View in: Pubmed

Improving Cancer Treatment via Mathematical Modeling: Surmounting the Challenges Is Worth the Effort. Cell. 2015 Nov 19; 163(5):1059-1063. View in: Pubmed

Dose-Dependent Mutation Rates Determine Optimum Erlotinib Dosing Strategies for EGFR Mutant Non-Small Cell Lung Cancer Patients. PLoS One. 2015; 10(11):e0141665. View in: Pubmed

An Evolutionary Approach for Identifying Driver Mutations in Colorectal Cancer. PLoS Comput Biol. 2015 Sep; 11(9):e1004350. View in: Pubmed

In situ single-cell analysis identifies heterogeneity for PIK3CA mutation and HER2 amplification in HER2-positive breast cancer. Nat Genet. 2015 Oct; 47(10):1212-9. View in: Pubmed

CXCR4 Regulates Extra-Medullary Myeloma through Epithelial-Mesenchymal-Transition-like Transcriptional Activation. Cell Rep. 2015 Jul 28; 12(4):622-35. View in: Pubmed

The Impact of Microenvironmental Heterogeneity on the Evolution of Drug Resistance in Cancer Cells. Cancer Inform. 2015; 14(Suppl 4):19-31. View in: Pubmed

Optimization of radiation dosing schedules for proneural glioblastoma. J Math Biol. 2016 Apr; 72(5):1301-36. View in: Pubmed

Studying clonal dynamics in response to cancer therapy using high-complexity barcoding. Nat Med. 2015 May; 21(5):440-8. View in: Pubmed

DNA copy number analysis of metastatic urothelial carcinoma with comparison to primary tumors. BMC Cancer. 2015 Apr 09; 15:242. View in: Pubmed

Polyploidy can drive rapid adaptation in yeast. Nature. 2015 Mar 19; 519(7543):349-52. View in: Pubmed

Stochastic tunneling and metastable states during the somatic evolution of cancer. Genetics. 2015 Apr; 199(4):1213-28. View in: Pubmed

JAK-STAT pathway activation in malignant and nonmalignant cells contributes to MPN pathogenesis and therapeutic response. Cancer Discov. 2015 Mar; 5(3):316-31. View in: Pubmed

Epigenetic diversity in hematopoietic neoplasms. Biochim Biophys Acta. 2014 Dec; 1846(2):477-84. View in: Pubmed

Dynamics of chronic myeloid leukemia response to dasatinib, nilotinib, and high-dose imatinib. Haematologica. 2014 Nov; 99(11):1701-9. View in: Pubmed

Most human non-GCIMP glioblastoma subtypes evolve from a common proneural-like precursor glioma. Cancer Cell. 2014 Aug 11; 26(2):288-300. View in: Pubmed

Non-cell-autonomous driving of tumour growth supports sub-clonal heterogeneity. Nature. 2014 Oct 02; 514(7520):54-8. View in: Pubmed

Clonal evolution in breast cancer revealed by single nucleus genome sequencing. Nature. 2014 Aug 14; 512(7513):155-60. View in: Pubmed

On the validity of using increases in 5-year survival rates to measure success in the fight against cancer. PLoS One. 2014; 9(7):e83100. View in: Pubmed

Histone modifications are associated with transcript isoform diversity in normal and cancer cells. PLoS Comput Biol. 2014 Jun; 10(6):e1003611. View in: Pubmed

FGFR3 expression in primary and metastatic urothelial carcinoma of the bladder. Cancer Med. 2014 Aug; 3(4):835-44. View in: Pubmed

Risk prediction for late-stage ovarian cancer by meta-analysis of 1525 patient samples. J Natl Cancer Inst. 2014 Apr 03; 106(5). View in: Pubmed

Understanding tissue context influences on intratumour heterogeneity. Nat Cell Biol. 2014 Apr; 16(4):301-2. View in: Pubmed

Evolution of acquired resistance to anti-cancer therapy. J Theor Biol. 2014 Aug 21; 355:10-20. View in: Pubmed

Integrative analysis of 1q23.3 copy-number gain in metastatic urothelial carcinoma. Clin Cancer Res. 2014 Apr 01; 20(7):1873-83. View in: Pubmed

Mathematical modeling of PDGF-driven glioblastoma reveals optimized radiation dosing schedules. Cell. 2014 Jan 30; 156(3):603-616. View in: Pubmed

Inference of tumor evolution during chemotherapy by computational modeling and in situ analysis of genetic and phenotypic cellular diversity. Cell Rep. 2014 Feb 13; 6(3):514-27. View in: Pubmed

Genetic and phenotypic diversity in breast tumor metastases. Cancer Res. 2014 Mar 01; 74(5):1338-48. View in: Pubmed

Variability in DNA methylation defines novel epigenetic subgroups of DLBCL associated with different clinical outcomes. Blood. 2014 Mar 13; 123(11):1699-708. View in: Pubmed

Safety and efficacy of pulsed imatinib with or without G-CSF versus continuous imatinib in chronic phase chronic myeloid leukaemia patients at 5 years follow-up. Br J Haematol. 2013 Dec; 163(5):674-6. View in: Pubmed

Stochastic Tunneling of Two Mutations in a Population of Cancer Cells. PLoS One. 2013; 8(6):e65724. View in: Pubmed

Patterns of proliferative activity in the colonic crypt determine crypt stability and rates of somatic evolution. PLoS Comput Biol. 2013; 9(6):e1003082. View in: Pubmed

Molecular profiling of human mammary gland links breast cancer risk to a p27(+) cell population with progenitor characteristics. Cell Stem Cell. 2013 Jul 03; 13(1):117-30. View in: Pubmed

Next-generation sequencing of paired tyrosine kinase inhibitor-sensitive and -resistant EGFR mutant lung cancer cell lines identifies spectrum of DNA changes associated with drug resistance. Genome Res. 2013 Sep; 23(9):1434-45. View in: Pubmed

Genomic characterization of metastatic urothelial carcinoma. J Clin Oncol. 2013 Feb 20; 31(6_suppl):247. View in: Pubmed

Peroxisome proliferator-activated receptor gamma (PPARG) gene amplifications in urothelial carcinoma (UC). J Clin Oncol. 2013 Feb 20; 31(6_suppl):279. View in: Pubmed

Epidermal growth factor receptor tyrosine kinase inhibitor-resistant disease. J Clin Oncol. 2013 Mar 10; 31(8):1070-80. View in: Pubmed

Aberration in DNA methylation in B-cell lymphomas has a complex origin and increases with disease severity. PLoS Genet. 2013; 9(1):e1003137. View in: Pubmed

DNA replication timing and higher-order nuclear organization determine single-nucleotide substitution patterns in cancer genomes. Nat Commun. 2013; 4:1502. View in: Pubmed

A physical sciences network characterization of non-tumorigenic and metastatic cells. Sci Rep. 2013; 3:1449. View in: Pubmed

Analyzing the association of SCNA boundaries with replication timing. Nat Biotechnol. 2012 Nov; 30(11):1045-6. View in: Pubmed

Effects of pharmacokinetic processes and varied dosing schedules on the dynamics of acquired resistance to erlotinib in EGFR-mutant lung cancer. J Thorac Oncol. 2012 Oct; 7(10):1583-93. View in: Pubmed

Evolutionary pathways in BRCA1-associated breast tumors. Cancer Discov. 2012 Jun; 2(6):503-11. View in: Pubmed

Selection pressure exerted by imatinib therapy leads to disparate outcomes of imatinib discontinuation trials. Haematologica. 2012 Oct; 97(10):1553-61. View in: Pubmed

Evolution of the cancer genome. Trends Genet. 2012 Apr; 28(4):155-63. View in: Pubmed

A race between tumor immunoescape and genome maintenance selects for optimum levels of (epi)genetic instability. PLoS Comput Biol. 2012; 8(2):e1002370. View in: Pubmed

Computational modeling of pancreatic cancer reveals kinetics of metastasis suggesting optimum treatment strategies. Cell. 2012 Jan 20; 148(1-2):362-75. View in: Pubmed

Combination of a novel gene expression signature with a clinical nomogram improves the prediction of survival in high-risk bladder cancer. Clin Cancer Res. 2012 Mar 01; 18(5):1323-33. View in: Pubmed

A mathematical methodology for determining the temporal order of pathway alterations arising during gliomagenesis. PLoS Comput Biol. 2012 Jan; 8(1):e1002337. View in: Pubmed

Fitness conferred by BCR-ABL kinase domain mutations determines the risk of pre-existing resistance in chronic myeloid leukemia. PLoS One. 2011; 6(11):e27682. View in: Pubmed

DNA replication timing and long-range DNA interactions predict mutational landscapes of cancer genomes. Nat Biotechnol. 2011 Nov 20; 29(12):1103-8. View in: Pubmed

Evolutionary modeling of combination treatment strategies to overcome resistance to tyrosine kinase inhibitors in non-small cell lung cancer. Mol Pharm. 2011 Dec 05; 8(6):2069-79. View in: Pubmed

The probable cell of origin of NF1- and PDGF-driven glioblastomas. PLoS One. 2011; 6(9):e24454. View in: Pubmed

What does physics have to do with cancer? Nat Rev Cancer. 2011 Aug 18; 11(9):657-70. View in: Pubmed

DNA methyltransferase 1 and DNA methylation patterning contribute to germinal center B-cell differentiation. Blood. 2011 Sep 29; 118(13):3559-69. View in: Pubmed

Optimization of dosing for EGFR-mutant non-small cell lung cancer with evolutionary cancer modeling. Sci Transl Med. 2011 Jul 06; 3(90):90ra59. View in: Pubmed

DNA secondary structures and epigenetic determinants of cancer genome evolution. Nat Struct Mol Biol. 2011 Jul 03; 18(8):950-5. View in: Pubmed

Dynamics of chronic myeloid leukemia response to long-term targeted therapy reveal treatment effects on leukemic stem cells. Blood. 2011 Aug 11; 118(6):1622-31. View in: Pubmed

A novel tumour-suppressor function for the Notch pathway in myeloid leukaemia. Nature. 2011 May 12; 473(7346):230-3. View in: Pubmed

Evolutionary dynamics of intratumor heterogeneity. PLoS One. 2011 Mar 30; 6(3):e17866. View in: Pubmed

Intratumor heterogeneity in evolutionary models of tumor progression. Genetics. 2011 Jun; 188(2):461-77. View in: Pubmed

Stochastic dynamics of cancer initiation. Phys Biol. 2011 Feb; 8(1):015002. View in: Pubmed

Evolutionary dynamics of BRCA1 alterations in breast tumorigenesis. J Theor Biol. 2011 Mar 21; 273(1):207-15. View in: Pubmed

The therapeutic implications of plasticity of the cancer stem cell phenotype. PLoS One. 2010 Dec 17; 5(12):e14366. View in: Pubmed

The origins and implications of intratumor heterogeneity. Cancer Prev Res (Phila). 2010 Nov; 3(11):1361-4. View in: Pubmed

A mathematical framework to determine the temporal sequence of somatic genetic events in cancer. Proc Natl Acad Sci U S A. 2010 Oct 12; 107(41):17604-9. View in: Pubmed

A differentiation-based microRNA signature identifies leiomyosarcoma as a mesenchymal stem cell-related malignancy. Am J Pathol. 2010 Aug; 177(2):908-17. View in: Pubmed

Evolutionary dynamics of tumor progression with random fitness values. Theor Popul Biol. 2010 Aug; 78(1):54-66. View in: Pubmed

A differentiation-based phylogeny of cancer subtypes. PLoS Comput Biol. 2010 May 06; 6(5):e1000777. View in: Pubmed

Cellular and genetic diversity in the progression of in situ human breast carcinomas to an invasive phenotype. J Clin Invest. 2010 Feb; 120(2):636-44. View in: Pubmed

Evolution of resistance to anti-cancer therapy during general dosing schedules. J Theor Biol. 2010 Mar 21; 263(2):179-88. View in: Pubmed

The evolution of tumor metastases during clonal expansion. J Theor Biol. 2010 Mar 07; 263(1):30-44. View in: Pubmed

Evolution of resistance to targeted anti-cancer therapies during continuous and pulsed administration strategies. PLoS Comput Biol. 2009 Nov; 5(11):e1000557. View in: Pubmed

A progenitor cell origin of myeloid malignancies. Proc Natl Acad Sci U S A. 2009 Sep 29; 106(39):16616-21. View in: Pubmed

Eradication of chronic myeloid leukemia stem cells: a novel mathematical model predicts no therapeutic benefit of adding G-CSF to imatinib. PLoS Comput Biol. 2009 Sep; 5(9):e1000503. View in: Pubmed

Evolutionary theory of cancer. Ann N Y Acad Sci. 2009 Jun; 1168:23-51. View in: Pubmed

A one-mutation mathematical model can explain the age incidence of acute myeloid leukemia with mutated nucleophosmin (NPM1). Haematologica. 2008 Aug; 93(8):1219-26. View in: Pubmed

Mathematical models of cancer stem cells. J Clin Oncol. 2008 Jun 10; 26(17):2854-61. View in: Pubmed

The evolution of two mutations during clonal expansion. Genetics. 2007 Dec; 177(4):2209-21. View in: Pubmed

Quantitative approaches to analyzing imatinib-treated chronic myeloid leukemia. Trends Pharmacol Sci. 2007 May; 28(5):197-9. View in: Pubmed

The emergence of tumor metastases. Cancer Biol Ther. 2007 Mar; 6(3):383-90. View in: Pubmed

(A)symmetric stem cell replication and cancer. PLoS Comput Biol. 2007 Mar 16; 3(3):e53. View in: Pubmed

Chronic myeloid leukemia blast crisis arises from progenitors. Stem Cells. 2007 May; 25(5):1114-8. View in: Pubmed

Mathematical models of targeted cancer therapy. Br J Cancer. 2006 Nov 06; 95(9):1136-41. View in: Pubmed

The age incidence of chronic myeloid leukemia can be explained by a one-mutation model. Proc Natl Acad Sci U S A. 2006 Oct 03; 103(40):14931-4. View in: Pubmed

Successful therapy must eradicate cancer stem cells. Stem Cells. 2006 Dec; 24(12):2603-10. View in: Pubmed

Evolution of resistance during clonal expansion. Genetics. 2006 Apr; 172(4):2557-66. View in: Pubmed

Dynamics of metastasis suppressor gene inactivation. J Theor Biol. 2006 Aug 07; 241(3):676-89. View in: Pubmed

Genetic instability and clonal expansion. J Theor Biol. 2006 Jul 07; 241(1):26-32. View in: Pubmed

Genetic instability and the quasispecies model. J Theor Biol. 2006 Jul 21; 241(2):216-22. View in: Pubmed

Evolution of resistance to cancer therapy. Curr Pharm Des. 2006; 12(3):261-71. View in: Pubmed

Stochastic dynamics of metastasis formation. J Theor Biol. 2006 Jun 21; 240(4):521-30. View in: Pubmed

Dynamics of colorectal cancer. Semin Cancer Biol. 2005 Dec; 15(6):484-93. View in: Pubmed

Synergy and discounting of cooperation in social dilemmas. J Theor Biol. 2006 Mar 21; 239(2):195-202. View in: Pubmed

Dynamics of chronic myeloid leukaemia. Nature. 2005 Jun 30; 435(7046):1267-70. View in: Pubmed

Chromosomal instability and human cancer. Philos Trans R Soc Lond B Biol Sci. 2005 Mar 29; 360(1455):631-5. View in: Pubmed

Can chromosomal instability initiate tumorigenesis? Semin Cancer Biol. 2005 Feb; 15(1):43-9. View in: Pubmed

Virus evolution within patients increases pathogenicity. J Theor Biol. 2005 Jan 07; 232(1):17-26. View in: Pubmed

Population genetics of tumor suppressor genes. J Theor Biol. 2005 Mar 07; 233(1):15-23. View in: Pubmed

Determinants of human immunodeficiency virus type 1 escape from the primary CD8+ cytotoxic T lymphocyte response. J Exp Med. 2004 Nov 15; 200(10):1243-56. View in: Pubmed

Some basic properties of immune selection. J Theor Biol. 2004 Jul 21; 229(2):179-88. View in: Pubmed

Evolutionary dynamics of tumor suppressor gene inactivation. Proc Natl Acad Sci U S A. 2004 Jul 20; 101(29):10635-8. View in: Pubmed

Linear model of colon cancer initiation. Cell Cycle. 2004 Mar; 3(3):358-62. View in: Pubmed

Dynamics of cancer progression. Nat Rev Cancer. 2004 Mar; 4(3):197-205. View in: Pubmed

Stochastic tunnels in evolutionary dynamics. Genetics. 2004 Mar; 166(3):1571-9. View in: Pubmed

Evolutionary dynamics of invasion and escape. J Theor Biol. 2004 Jan 21; 226(2):205-14. View in: Pubmed

Evolutionary dynamics of escape from biomedical intervention. Proc Biol Sci. 2003 Dec 22; 270(1533):2573-8. View in: Pubmed

Somatic selection for and against cancer. J Theor Biol. 2003 Dec 07; 225(3):377-82. View in: Pubmed

The linear process of somatic evolution. Proc Natl Acad Sci U S A. 2003 Dec 09; 100(25):14966-9. View in: Pubmed

Stochastic elimination of cancer cells. Proc Biol Sci. 2003 Oct 07; 270(1528):2017-24. View in: Pubmed

Local regulation of homeostasis favors chromosomal instability. Curr Biol. 2003 Apr 01; 13(7):581-4. View in: Pubmed

Evolution: the good, the bad and the lonely. Nature. 2002 Oct 17; 419(6908):677, 679. View in: Pubmed